HONG KONG, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Abits Group Inc (NASDAQ: ABTS) (the “Company”), a new generation digital center with inhouse bitcoin mining operations, today announced the closing of the previously announced registered direct offering with institutional investors of approximately $2.1 million of Ordinary Shares and pre-funded warrants at a price of $2.65 per Ordinary Share. The entire transaction was priced at the market under Nasdaq rules. The offering consisted of the sale of 792,452 Ordinary ...

Core Insights - E.F. Hutton acted as the exclusive placement agent for a $5 million registered direct offering by VCI Global Limited, a company focused on technology and digital infrastructure solutions [1][2][3] Group 1: Offering Details - The offering is structured in multiple tranches and is expected to generate gross proceeds of $5 million before fees and expenses [2] - The transaction was facilitated with Esousa Group Holdings, LLC, a family office based in New York [2] - The net proceeds from the offering will be used for working capital and general corporate purposes, including the development of technology and digital infrastructure platforms [4] Group 2: Company Background - E.F. Hutton & Co. is an investment bank and broker-dealer headquartered in Manhattan, providing advisory and financing solutions to a diverse range of clients [6] - The firm has a global footprint and offers comprehensive investment banking services, including capital markets, private placements, and M&A advisory [6] - E.F. Hutton's CEO emphasized the firm's commitment to supporting innovative, growth-oriented companies with tailored capital solutions [3]

Core Viewpoint - Insight Molecular Diagnostics Inc. has announced a registered direct offering of 4,525,976 shares of common stock at an offering price of $5.75 per share, expected to raise approximately $26 million before expenses [1][2]. Group 1: Offering Details - The offering is set to close on February 12, 2026, pending customary closing conditions [1]. - Lake Street Capital Markets, LLC is acting as the sole placement agent for the offering [2]. - The purchase price for pre-funded warrants is the same as the common stock price, minus an exercise price of $0.0001 per share [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, particularly for research and development in the transplantation category [2]. - The company aims to expand its GraftAssure product line to include heart transplant rejection testing, in addition to kidney transplant rejection testing [3]. Group 3: Shareholder Participation - Bio-Rad Laboratories, Inc., a significant shareholder of Insight Molecular Diagnostics, participated in the offering on the same terms as other investors [3]. Group 4: Regulatory Information - The securities are being offered under a "shelf" registration statement filed with the SEC, which was declared effective on August 7, 2024 [4]. - A final prospectus supplement will be filed with the SEC and will be available on their website [4]. Group 5: Company Overview - Insight Molecular Diagnostics is focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [6]. - The company offers various products, including GraftAssureCore™, GraftAssureIQ™, and others [6].

Core Viewpoint - Inspira Technologies has announced a registered direct offering of 6,785,715 ordinary shares at a price of $0.70 per share, expected to raise approximately $4.75 million before expenses [1][2]. Group 1: Offering Details - The offering is set to close on or about February 6, 2026, pending customary closing conditions [2]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for this offering [2]. Group 2: Securities and Registration - The ordinary shares are being offered under a prospectus supplement to be filed with the SEC, linked to the Company's effective shelf registration statement [3]. - The warrants issued in a concurrent private placement will have an exercise price of $0.70 per share and will be exercisable six months after issuance, expiring in 5.5 years [1][3]. Group 3: Existing Warrants Amendment - Existing warrants issued to the investor in December 2023, originally priced at $1.28, will be amended to a reduced exercise price of $0.70 per share, expiring five years from the closing date [5]. Group 4: Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA™ ART100 system [6]. - The company is developing the INSPIRA ART500 system for oxygenation while patients remain awake and is advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring [6]. - With a growing IP portfolio and strategic operational streamlining, Inspira Technologies is positioned as an attractive player in the life-support and MedTech sectors [6].

Core Viewpoint - Innventure, Inc. has successfully closed a registered direct offering of common stock, raising approximately $40 million to strengthen its balance sheet and support its long-term growth strategy [1][3]. Group 1: Offering Details - The offering was made to four institutional investors and resulted in gross proceeds of about $40 million before expenses [1]. - The net proceeds will be used to redeem outstanding convertible debentures and for working capital, including the potential conversion of approximately $8 million of intercompany convertible debt into equity in Accelsius [2]. - The offering was conducted under an effective shelf registration statement filed with the SEC [4]. Group 2: Strategic Implications - The CEO of Innventure emphasized that the capital raised will enhance the company's ability to unlock value from breakthrough technologies and increase ownership in Accelsius, which is positioned in a growing market with a sales opportunity pipeline exceeding $1 billion [3]. - The company aims to drive durable shareholder value as it progresses through future quarters and years [3]. Group 3: Company Overview - Innventure focuses on building companies with billion-dollar valuations by commercializing breakthrough technology solutions and bridging the gap between corporate innovation and commercialization [6].

Core Viewpoint - Innventure, Inc. has entered into securities purchase agreements to sell 11,428,572 shares of common stock for approximately $40 million, aimed at repaying outstanding convertible debentures and for working capital purposes [1][2]. Group 1: Offering Details - The offering is expected to close on or about January 14, 2026, pending customary closing conditions [1]. - Titan Partners is acting as the sole placement agent for the offering [3]. - The offering is made under an effective shelf registration statement on Form S-3, filed with the SEC on December 23, 2025, and declared effective on January 9, 2026 [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to repay all outstanding obligations under convertible debentures and for general corporate purposes, including the repayment of approximately $8 million in intercompany convertible debt [2]. Group 3: Company Overview - Innventure is an industrial growth conglomerate focused on building companies with billion-dollar valuations by commercializing breakthrough technology solutions [6]. - The company aims to bridge the gap between corporate innovation and commercialization through value-driven partnerships and operational expertise [6].

Core Viewpoint - Cemtrex, Inc. has announced a definitive agreement to purchase approximately 1,469,507 shares at a price of $2.722 per share, expecting gross proceeds of $4 million [1]. Group 1: Transaction Details - The transaction is expected to close on or about January 9, 2025, pending customary closing conditions [2]. - The net proceeds from the offering will be used for general corporate purposes, including working capital and potential acquisitions [2]. Group 2: Regulatory Information - The offering is made under an effective shelf registration statement on Form S-3, previously filed with the SEC and declared effective on February 3, 2025 [3]. - A final prospectus supplement and accompanying prospectus will be filed with the SEC, providing detailed terms of the offering [3]. Group 3: Company Overview - Cemtrex, Inc. operates in the Security, Industrial, and Aerospace & Defense sectors, providing advanced security technology and industrial services [6]. - The Security segment, led by Vicon Industries, offers video management software and integrated surveillance solutions [6]. - The Industrial segment provides specialized services such as rigging and equipment installation, while the Aerospace & Defense segment focuses on engineering and instrumentation solutions [6].

Core Viewpoint - ArrowMark Financial Corp. has entered into a securities purchase agreement to sell 673,249 shares of common stock at a price of $22.28 per share, which is slightly above the Net Asset Value of $22.20, indicating a positive impact for current shareholders [1]. Group 1: Offering Details - The registered direct offering is expected to generate proceeds of approximately $14.99 million, excluding legal and administrative expenses [2]. - The offering is conducted under a "shelf" registration statement filed with the SEC, allowing for the sale of securities through a prospectus [3]. Group 2: Company Overview - ArrowMark Financial Corp. is a non-diversified, closed-end fund listed on NASDAQ under the symbol "BANX," with an investment objective focused on providing current income primarily through investments in regulatory capital securities of financial institutions [5].

Core Viewpoint - Mangoceuticals, Inc. has entered into agreements for a registered direct offering and a concurrent private placement, expecting to raise approximately $2.5 million in gross proceeds [1][3]. Group 1: Offering Details - The transactions involve the sale of 1,930,502 Common Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one PIPE Common Warrant at an exercise price of $1.4245 [2]. - The offering price per Common Unit is set at $1.295, while the Pre-Funded Unit is priced at $1.29499, accounting for a minimal exercise price of $0.00001 per Pre-Funded Warrant [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. Group 2: Use of Proceeds - The net proceeds from the offerings, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Legal and Regulatory Information - Aegis Capital Corp. is the exclusive placement agent for the offerings, and Lucosky Brookman LLP is acting as counsel to the Company [4]. - The registered direct offering is made under an effective shelf registration statement previously filed with the SEC [4]. - The securities in the private placement are not registered under the Securities Act and are offered only to accredited investors [5]. Group 4: Company Overview - Mangoceuticals, Inc. focuses on developing health and wellness products via a secure telemedicine platform, particularly in men's health sectors such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [8]. - The telemedicine platform allows consumers to request prescriptions, which are reviewed by a physician and fulfilled through a partner compounding pharmacy [9].

Core Viewpoint - Inspira Technologies has announced a definitive agreement for a registered direct offering of ordinary shares, aiming to raise approximately $1.8 million to support its strategic initiatives and operations [1][2][6]. Group 1: Registered Direct Offering - The company will issue and sell 1,565,217 ordinary shares at a price of $1.15 per share, resulting in gross proceeds of about $1.8 million [2]. - The offering is expected to close on or about December 16, 2025, pending customary closing conditions [2]. Group 2: Standby Equity Purchase Agreement (SEPA) - Inspira has entered into a SEPA with YA, allowing the company to sell up to $25 million of its ordinary shares over a 36-month period at its discretion [4]. - There are no minimum purchase requirements under the SEPA, and the company is not obligated to draw on this facility [4][9]. Group 3: Use of Proceeds - The net proceeds from the registered direct offering and any future proceeds from the SEPA will be used for working capital and general corporate purposes, specifically to support the company's strategic roadmap and planned operations [6]. Group 4: Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, with products like the INSPIRA™ ART100 system and the upcoming INSPIRA ART500 [8]. - The company is positioned as an attractive platform within the life-support and MedTech landscape, supported by a growing IP portfolio and multiple cleared products [8].